How do airplanes fly? An aerospace engineer explains the physics of flight 
Could a telescope ever see the beginning of time? An astronomer explains 
Why now is the time to address humanity’s impact on the moon 
Archeoastronomy uses the rare times and places of previous total solar eclipses to help us measure history 
The rising flood of space junk is a risk to us on Earth – and governments are on the hook 
Orbital resonance − the striking gravitational dance done by planets with aligning orbits 
Six space missions to look forward to in 2024 
Why is the universe ripping itself apart? A new study of exploding stars shows dark energy may be more complicated than we thought 
Eggs from men, sperm from women: how stem cell science may change how we reproduce 
Dark energy is one of the biggest puzzles in science and we're now a step closer to understanding it 
Our survey of the sky is uncovering the secrets of how planets are born 
Why some people don't trust science – and how to change their minds 
The brain is the most complicated object in the universe. This is the story of scientists’ quest to decode it – and read people’s minds 
The brightest object in the universe is a black hole that eats a star a day 
Another major development in the science of finding a cure for cancer was reported recently. A group of researchers from the University of Pennsylvania revealed their findings centered on the tumors’ self-destructive quality that can be exploited in finding a way to treat cancer.
Alternative approach to stop tumor growth
The MYC gene is known for its role in normal cell growth. But when affected by cancer, MYC activates a chain reaction leading to the fast growth of tumors. Scientists have been directing various studies that aim to specifically attack MYC, though this goal has proven to be very difficult to carry out.
In the study published by UPenn researchers on the Nature Cell Biology journal on Monday, they shed light on other ways to stop the said chain reaction aside from directly attacking MYC. In doing so, they found a pathway they consider to be MYC’s Achilles’ heel. This approach mainly involves a protein called ATF4.
One of the steps identified is controlled by the kinase called PERK that activates ATF4. But researchers found that targeting PERK along does not always affect MYC because of a second kinase called GCN2. These two enzymes have parallel functions in the entire process.
“What we've learned is that we need to go further downstream to block tumor growth in a way that cancer cells can't easily escape, and our study identifies the target to do just that,” co-senior author Dr. Constantinos Koumenis explained. This led them to the approach of directly targeting ATF4 since it is identified as the converging point for both PERK and GCN2.
Targeting ATF4 blocks tumor growth on cells and mice
Aside from being the converging point of PERK and GCN2, the scientists learned that ATF4 activates the genes MYC needs for growth and regulates the rate of the production of the 4E-BP protein. When ATF4 in cells and mice is targeted, there is no control in the production of the said protein resulting in stress and ultimately leading to the death of tumor cells.
Tests show that tumors stopped growing on mice with lymphoma and colorectal cancer. The same over-expression of 4E-BP and ATF4 was also observed in human cells. This increases the chance of replicating the said result on mice when the same approach is applied to humans, thereby, sparking hopes in developing improved cancer treatments.
